CL2015000345A1 - Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib. - Google Patents

Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib.

Info

Publication number
CL2015000345A1
CL2015000345A1 CL2015000345A CL2015000345A CL2015000345A1 CL 2015000345 A1 CL2015000345 A1 CL 2015000345A1 CL 2015000345 A CL2015000345 A CL 2015000345A CL 2015000345 A CL2015000345 A CL 2015000345A CL 2015000345 A1 CL2015000345 A1 CL 2015000345A1
Authority
CL
Chile
Prior art keywords
cobimetinib
vemurafenib
melanoma
administration
combination
Prior art date
Application number
CL2015000345A
Other languages
English (en)
Inventor
Gordon Bray
Iris T Chan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49035547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000345(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2015000345A1 publication Critical patent/CL2015000345A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0241—Advertisements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Business, Economics & Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Strategic Management (AREA)
  • Accounting & Taxation (AREA)
  • Development Economics (AREA)
  • Finance (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Game Theory and Decision Science (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • General Business, Economics & Management (AREA)
  • Marketing (AREA)
  • Economics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
CL2015000345A 2012-08-17 2015-02-13 Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib. CL2015000345A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261684673P 2012-08-17 2012-08-17
US201261705575P 2012-09-25 2012-09-25
US201261706026P 2012-09-26 2012-09-26
US201261722725P 2012-11-05 2012-11-05
US201361780708P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
CL2015000345A1 true CL2015000345A1 (es) 2015-05-22

Family

ID=49035547

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000345A CL2015000345A1 (es) 2012-08-17 2015-02-13 Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib.

Country Status (31)

Country Link
US (3) US11087354B2 (es)
EP (1) EP2884979B1 (es)
JP (2) JP6335169B2 (es)
KR (6) KR20210108502A (es)
CN (2) CN104640545A (es)
AU (1) AU2013304021B2 (es)
BR (1) BR112015003418A2 (es)
CA (2) CA2879252C (es)
CL (1) CL2015000345A1 (es)
CO (1) CO7180225A2 (es)
DK (1) DK2884979T3 (es)
EA (1) EA033573B1 (es)
ES (1) ES2743427T3 (es)
HK (1) HK1206605A1 (es)
HR (1) HRP20191533T1 (es)
HU (1) HUE044789T2 (es)
IL (1) IL237065B (es)
LT (1) LT2884979T (es)
MX (1) MX367970B (es)
MY (1) MY180613A (es)
NZ (1) NZ744862A (es)
PE (1) PE20151156A1 (es)
PH (1) PH12015500186A1 (es)
PL (1) PL2884979T3 (es)
PT (1) PT2884979T (es)
RS (1) RS59113B1 (es)
SG (3) SG11201500582UA (es)
SI (1) SI2884979T1 (es)
UA (1) UA114923C2 (es)
WO (1) WO2014027056A1 (es)
ZA (1) ZA201500348B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013055874A2 (en) 2011-10-14 2013-04-18 Genentech, Inc. Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
DK2884979T3 (da) * 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
CN107073121A (zh) * 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
CZ2015250A3 (cs) * 2015-04-14 2016-10-26 Zentiva, K.S. Amorfní formy vemurafenibu
CN107801378A (zh) * 2015-05-22 2018-03-13 普莱希科公司 用于治疗braf‑v600相关的疾病的plx‑8394或plx‑7904
CA2987912C (en) * 2015-06-30 2023-01-24 Genentech, Inc. Immediate-release tablets containing a drug and processes for forming the tablets
AU2016349279A1 (en) 2015-11-03 2018-05-10 Board Of Regents, The University Of Texas System Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer
CN121154828A (zh) * 2015-11-19 2025-12-19 豪夫迈·罗氏有限公司 使用b-raf抑制剂和免疫检查点抑制剂治疗癌症的方法
WO2017095826A1 (en) * 2015-11-30 2017-06-08 The Regents Of The University Of California Combination therapy for treatment of melanoma
AU2017311585A1 (en) 2016-08-12 2019-02-28 Genentech, Inc. Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a VEGF inhibitor
AU2017335839A1 (en) 2016-09-29 2019-04-18 Genentech, Inc. Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a taxane
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
WO2019139970A1 (en) * 2018-01-09 2019-07-18 Duke University Topical administration of mek inhibiting agents for the treatment of skin disorders
CN109879855B (zh) * 2019-03-26 2021-01-05 中国医学科学院医药生物技术研究所 靶向肿瘤细胞表面pd-l1分子的抑制剂及其应用
US20240000789A1 (en) * 2020-05-12 2024-01-04 Novartis Ag Therapeutic combinations comprising a craf inhibitor
JP2024509269A (ja) 2021-03-09 2024-02-29 ジェネンテック， インコーポレイテッド 脳がんの治療における使用のためのベルバラフェニブ
EP4319749A1 (en) 2021-04-06 2024-02-14 Genentech, Inc. Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab
AU2023269182A1 (en) * 2022-05-09 2024-11-14 Yale University Immunotherapy of skin cancer using mpla-loaded hpg nanoparticles
AU2024290776A1 (en) * 2023-07-03 2026-01-15 Országos Onkológiai Intézet Cse inhibitor for use in the treatment of a tumor in combination with a mapk inhibitor

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2466762A1 (en) 2001-12-04 2003-06-12 Onyx Pharmaceuticals, Inc. Raf-mek-erk pathway inhibitors to treat cancer
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AU2003286447A1 (en) 2003-10-16 2004-06-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
CA2546353A1 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
CA2550361C (en) 2003-12-19 2014-04-29 Prabha Ibrahim Compounds and methods for development of ret modulators
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
CN102206216B (zh) 2005-06-22 2014-11-12 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
PL1913157T5 (pl) 2005-06-28 2017-09-29 Genentech Inc Mutacje EGFR i KRAS do prognozowania reakcji pacjenta na leczenie inhibitorem EGFR
US9095581B2 (en) 2005-07-21 2015-08-04 Ardea Biosciences, Inc. Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US7713960B2 (en) 2005-07-22 2010-05-11 University Of South Florida Inhibition of the Raf/Mek/P-Erk pathway for treating cancer
EP2073810B1 (en) * 2006-09-13 2011-08-31 Takeda Pharmaceutical Company Limited Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer, autoimmune disorders and hiv infection
HRP20110498T1 (hr) 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
KR20090071603A (ko) 2006-09-19 2009-07-01 노파르티스 아게 Ｒａｆ 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
ES2426814T3 (es) 2007-03-13 2013-10-25 Amgen Inc. Mutaciones de K-ras y B-raf y terapia con anticuerpos anti-EGFr
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
UA99731C2 (ru) 2007-07-30 2012-09-25 Ардеа Биосайенсис, Инк Кристаллические полиморфные формы n-(ариламино)сульфонамидов как ингибиторы мэк, композиция (варианты) и применение
JP2011513332A (ja) 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
ES2392482T3 (es) 2008-02-29 2012-12-11 Array Biopharma, Inc. Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF
PE20091561A1 (es) 2008-02-29 2009-10-30 Array Biopharma Inc Compuestos inhibidores de raf y metodos para su uso
JP2011513331A (ja) 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
KR101739994B1 (ko) 2009-04-03 2017-05-25 에프. 호프만-라 로슈 아게 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
IN2012DN01403A (es) 2009-08-24 2015-06-05 Genentech Inc
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
KR101489045B1 (ko) * 2009-10-12 2015-02-02 에프. 호프만-라 로슈 아게 Ｐｉ3ｋ 억제자 및 ｍｅｋ 억제자의 조합
CN102665720A (zh) 2009-10-12 2012-09-12 葛兰素史密斯克莱有限责任公司 组合
WO2011104694A2 (en) * 2010-02-26 2011-09-01 GAMMAGENETICS Sàrl Detection of braf v600e mutation by allele specific real time quantitative pcr (as-qpcr) using locked nucleic acids primers and beacon probes
CN103038364A (zh) 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US8426418B2 (en) 2010-08-27 2013-04-23 CollabRx Inc. Method to treat melanoma in BRAF inhibitor-resistant subjects
CN103370064A (zh) * 2010-09-03 2013-10-23 百时美施贵宝公司 使用水溶性抗氧化剂的药物制剂
US20130217710A1 (en) 2010-11-05 2013-08-22 Glaxosmithkline Intellectual Property (No.2) Limited Methods for treating cancer
CA2818544A1 (en) 2010-11-19 2012-05-24 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment with braf inhibitor
WO2012068562A2 (en) * 2010-11-19 2012-05-24 The Regents Of The University Of California Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
US9295669B2 (en) * 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
US20130172375A1 (en) 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
DK2884979T3 (da) * 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
EP2958592A1 (en) 2013-02-22 2015-12-30 F. Hoffmann-La Roche AG Methods of treating cancer and preventing drug resistance

Also Published As

Publication number Publication date
MY180613A (en) 2020-12-03
DK2884979T3 (da) 2019-09-02
BR112015003418A2 (pt) 2017-07-04
IL237065A0 (en) 2015-03-31
KR20170044759A (ko) 2017-04-25
PE20151156A1 (es) 2015-08-19
CA2879252C (en) 2017-10-10
HK1206605A1 (en) 2016-01-15
SG11201500582UA (en) 2015-04-29
EP2884979B1 (en) 2019-06-26
JP2015531763A (ja) 2015-11-05
EA033573B1 (ru) 2019-11-06
EP2884979A1 (en) 2015-06-24
RS59113B1 (sr) 2019-09-30
CO7180225A2 (es) 2015-02-09
AU2013304021B2 (en) 2016-09-15
HRP20191533T1 (hr) 2019-11-29
UA114923C2 (uk) 2017-08-28
CN104640545A (zh) 2015-05-20
ES2743427T3 (es) 2020-02-19
CA2879252A1 (en) 2014-02-20
MX2015002031A (es) 2015-06-05
LT2884979T (lt) 2019-09-10
KR20150038068A (ko) 2015-04-08
SG10201913359TA (en) 2020-02-27
NZ744862A (en) 2019-06-28
SI2884979T1 (sl) 2019-10-30
WO2014027056A1 (en) 2014-02-20
US11783366B2 (en) 2023-10-10
SG10201708494QA (en) 2017-11-29
KR20220165811A (ko) 2022-12-15
ZA201500348B (en) 2019-07-31
US20240046303A1 (en) 2024-02-08
KR20240146112A (ko) 2024-10-07
HUE044789T2 (hu) 2019-11-28
US20140093568A1 (en) 2014-04-03
JP6335169B2 (ja) 2018-05-30
EA201590262A1 (ru) 2015-06-30
US11087354B2 (en) 2021-08-10
PH12015500186A1 (en) 2015-04-06
CA2928396A1 (en) 2014-02-20
US20220172244A1 (en) 2022-06-02
PL2884979T3 (pl) 2019-11-29
KR20190057421A (ko) 2019-05-28
KR20210108502A (ko) 2021-09-02
CN110251512A (zh) 2019-09-20
AU2013304021A1 (en) 2015-02-12
IL237065B (en) 2020-07-30
PT2884979T (pt) 2019-09-04
US12354130B2 (en) 2025-07-08
JP2017160214A (ja) 2017-09-14
MX367970B (es) 2019-09-11

Similar Documents

Publication Publication Date Title
CL2015000345A1 (es) Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib.
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
BR112014031262A2 (pt) composições biocatalisadoras inovadoras e processos para uso.
CO6900149A2 (es) Una composición farmacéutica que comprende los fitocanabinoides canabidivarina (cbdv) y canabidiol (cbd)
BR112015000420A2 (pt) composto, composição farmacêutica, e, uso de um composto
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
CL2015000294A1 (es) Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor del receptor del factor de crecimiento epidermico y opcionalmente un inhibidor pi3halpha y uso en el tratamiento de una enfermedad proliferativa.
EP2922877A4 (en) IMPROVED PEPTIDATE MEDICINES
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
CL2014001047A1 (es) Compuestos heterociclicos derivados de pirazina; composicion y combinacion farmaceutica que los contienen y el uso en enfermedades respiratorias y alergicas.
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
BR112014029642A2 (pt) composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
CL2015002803A1 (es) Una composición no nematicida y uso de los mismos
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
GB201513741D0 (en) Positioning, quick-release bioadhesion agent and use
BR112014021068A8 (pt) inibidor de uma interação entre fosfatidilserina e um receptor tim, composição farmacêutica e uso de um inibidor
CL2014003283A1 (es) Formulación farmacéutica.
CL2015001458A1 (es) Composición simbiotica y el uso de la misma.
EP2976091C0 (de) Antioxidativ wirksame zusammensetzung und deren verwendung
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
BR112013012175A2 (pt) combinação, coadministração, uso e método
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.